國立虎尾科技大學 |

Medical cannabis and the effects of cannabinoids on fighting cancer, multiple sclerosis, epilepsy, Parkinson's, and other neurodegenerative diseases

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Medical cannabis and the effects of cannabinoids on fighting cancer, multiple sclerosis, epilepsy, Parkinson's, and other neurodegenerative diseases/ Rana R. Zeine and Brian W. Teasdale.
其他作者:	Zeine, Rana,
出版者:	Hershey, Pennsylvania :IGI Global, : 2023.,
面頁冊數:	1 online resource (406 p.)
標題:	Marijuana - Therapeutic use. -
電子資源:	http://services.igi-global.com/resolvedoi/resolve.aspx?doi=10.4018/978-1-6684-5652-1
ISBN:	9781668456538 (electronic bk.)

Medical cannabis and the effects of cannabinoids on fighting cancer, multiple sclerosis, epilepsy, Parkinson's, and other neurodegenerative diseases
Medical cannabis and the effects of cannabinoids on fighting cancer, multiple sclerosis, epilepsy, Parkinson's, and other neurodegenerative diseases[electronic resource] /Rana R. Zeine and Brian W. Teasdale. - Hershey, Pennsylvania :IGI Global,2023. - 1 online resource (406 p.)

Includes bibliographical references and index.

Chapter 1. Medicinal cannabis for Alzheimer's disease -- Chapter 2. Protective effects of cannabis in neuroinflammation-mediated Alzheimer's disease -- Chapter 3. Cannabinoid efficacy for developmental epileptic encephalopathy (DEE)intractable seizure control: a systematic review of the literature -- Chapter 4. Medical cannabis in the treatment of epilepsy -- Chapter 5. Anti-tumor effects of cannabinoids in brain, lung, breast, prostate, colorectal, and pancreatic cancers: a systematic review of the literature -- Chapter 6. Cannabinoid neurobiology and medical cannabis intervention for amyotrophic lateral sclerosis (ALS): understanding the molecular mechanisms of action -- Chapter 7. Role of cannabinoids in the regulation of amyotrophic lateral sclerosis (ALS) -- Chapter 8. Neurobiology of cannabinoids and medical cannabis in therapeutic intervention for multiple sclerosis: understanding the molecular mechanisms of action -- Chapter 9. Pros and cons of cannabinoids as a potential therapeutic target for treating Parkinson's disease: cannabinoid receptor-mediated mechanism of action -- Chapter 10. The uses of cannabinoids in medicine and their spectroscopic applications -- Chapter 11. Therapeutic advantages of cannabimimetic plants: can they substitute medical cannabis? -- Chapter 12. History and legislative changes governing medical cannabis in Indonesia -- Chapter 13. A case study on the integration of cannabis law enforcement in new jersey.

"Research into the efficacy of medical marijuana is currently at different stages for different types of diseases. The most advanced studies in humans provide moderate-quality evidence for moderate effects that benefit patients withParkinson Disease and Multiple Sclerosis. There is also low-quality evidence for mild-to-moderate effects that benefit patients with Epilepsy and Huntington Disease. The best success in reducing spasticity, relieving pain, decreasing bladder overactivity, reducing anxiety and improving quality of sleep was achieved using a 50:50 mixture of Cannabidiol (CBD):delta-9-THC. Reducing frequency and duration of seizures in children with intractable epilepsy is achieved using CBD alone. Future studies can hopefully improve the quality of evidence by including control groups, recruiting more participants, and following them up for longer periods of time. In the meanwhile, the cellular and molecular mechanisms responsible for alleviating these neurological symptoms in animals and humans are being investigated. Some of the anti-inflammatory and neuroprotective effects are mediated through one or both of the cannabinoid receptors CB1 and CB2 distributed on immune and neural cells, while some of the anti-epileptic effects are mediated through other receptors found in the central nervous system. Animal studies show that cannabinoids are effective anti-inflammatory and anti-tumor agents. In experimental xenograft models for brain cancer, lung, breast, colorectal, pancreatic and other cancers, treatment with either CBD alone or in mixtures with THC, significantly shrinks the tumors, inhibits tumor cell migration, slows metastasis, disrupts tumor blood vessel formation (angiogenesis), inhibits tumor cell proliferation and increases tumor cell death. Future studies are warranted to investigate these anti-tumor effects in human cancer patients, however, a small study onadozen brain cancer patients demonstrated a modest increase in overall survival, and a case study on a lung cancer patient who refused chemotherapy and used cannabinoids instead reported a remarkable regression of the lung cancer tumors. Research efforts are intensifying to elucidate the multitude of cell signaling mechanisms that might be involved in mediating these remarkable anti-cancer and anti-angiogenic effects. The implications are that the next decade will be the dawnof a new era of pharmacotherapeutic applications of medical marijuana treatments in oncology for all cancer types, neurology for all movement disorders, demyelinative and dementia-causing neurodegenerative diseases, rheumatology and gastroenterology for all autoimmune and inflammatory disorders, and palliative care medicine for anxiety and pain management. This publication will include 15 chapters by experts on the use of cannabinoids and medical marijuana in different typesofcancer and different types of neurologic or inflammatory diseases. Some authors will discuss the physiologic and biochemical mechanisms while others will report on clinical benefits and pharmacological challenges"--

ISBN: 9781668456538 (electronic bk.)Subjects--Topical Terms:

1155356
Marijuana
--Therapeutic use.Index Terms--Genre/Form:

554714
Electronic books.

LC Class. No.: RM666.C266 / M43 2023e

Dewey Class. No.: 615.3/23648

National Library of Medicine Call No.: WB 925 / .M43 2023e

Medical cannabis and the effects of cannabinoids on fighting cancer, multiple sclerosis, epilepsy, Parkinson's, and other neurodegenerative diseases
LDR:05601nam a2200277 a 4500 001 1155664
006 m d
007 cr nn muauu
008 250625s2023 pau fob 001 0 eng d
020 $a 9781668456538 (electronic bk.)
020 $a 1668456524
020 $a 9781668456521
035 $a (CaBNVSL)slc00004108
035 $a (OCoLC)1372506850
035 $a 00296569
040 $a CaBNVSL $b eng $c CaBNVSL $d CaBNVSL
041 0 $a eng
050 4 $a RM666.C266 $b M43 2023e
060 0 0 $a WB 925 $b .M43 2023e
082 0 4 $a 615.3/23648 $2 23
245 0 0 $a Medical cannabis and the effects of cannabinoids on fighting cancer, multiple sclerosis, epilepsy, Parkinson's, and other neurodegenerative diseases $h [electronic resource] / $c Rana R. Zeine and Brian W. Teasdale.
260 $a Hershey, Pennsylvania : $b IGI Global, $c 2023.
300 $a 1 online resource (406 p.)
504 $a Includes bibliographical references and index.
505 0 $a Chapter 1. Medicinal cannabis for Alzheimer's disease -- Chapter 2. Protective effects of cannabis in neuroinflammation-mediated Alzheimer's disease -- Chapter 3. Cannabinoid efficacy for developmental epileptic encephalopathy (DEE)intractable seizure control: a systematic review of the literature -- Chapter 4. Medical cannabis in the treatment of epilepsy -- Chapter 5. Anti-tumor effects of cannabinoids in brain, lung, breast, prostate, colorectal, and pancreatic cancers: a systematic review of the literature -- Chapter 6. Cannabinoid neurobiology and medical cannabis intervention for amyotrophic lateral sclerosis (ALS): understanding the molecular mechanisms of action -- Chapter 7. Role of cannabinoids in the regulation of amyotrophic lateral sclerosis (ALS) -- Chapter 8. Neurobiology of cannabinoids and medical cannabis in therapeutic intervention for multiple sclerosis: understanding the molecular mechanisms of action -- Chapter 9. Pros and cons of cannabinoids as a potential therapeutic target for treating Parkinson's disease: cannabinoid receptor-mediated mechanism of action -- Chapter 10. The uses of cannabinoids in medicine and their spectroscopic applications -- Chapter 11. Therapeutic advantages of cannabimimetic plants: can they substitute medical cannabis? -- Chapter 12. History and legislative changes governing medical cannabis in Indonesia -- Chapter 13. A case study on the integration of cannabis law enforcement in new jersey.
520 $a "Research into the efficacy of medical marijuana is currently at different stages for different types of diseases. The most advanced studies in humans provide moderate-quality evidence for moderate effects that benefit patients withParkinson Disease and Multiple Sclerosis. There is also low-quality evidence for mild-to-moderate effects that benefit patients with Epilepsy and Huntington Disease. The best success in reducing spasticity, relieving pain, decreasing bladder overactivity, reducing anxiety and improving quality of sleep was achieved using a 50:50 mixture of Cannabidiol (CBD):delta-9-THC. Reducing frequency and duration of seizures in children with intractable epilepsy is achieved using CBD alone. Future studies can hopefully improve the quality of evidence by including control groups, recruiting more participants, and following them up for longer periods of time. In the meanwhile, the cellular and molecular mechanisms responsible for alleviating these neurological symptoms in animals and humans are being investigated. Some of the anti-inflammatory and neuroprotective effects are mediated through one or both of the cannabinoid receptors CB1 and CB2 distributed on immune and neural cells, while some of the anti-epileptic effects are mediated through other receptors found in the central nervous system. Animal studies show that cannabinoids are effective anti-inflammatory and anti-tumor agents. In experimental xenograft models for brain cancer, lung, breast, colorectal, pancreatic and other cancers, treatment with either CBD alone or in mixtures with THC, significantly shrinks the tumors, inhibits tumor cell migration, slows metastasis, disrupts tumor blood vessel formation (angiogenesis), inhibits tumor cell proliferation and increases tumor cell death. Future studies are warranted to investigate these anti-tumor effects in human cancer patients, however, a small study onadozen brain cancer patients demonstrated a modest increase in overall survival, and a case study on a lung cancer patient who refused chemotherapy and used cannabinoids instead reported a remarkable regression of the lung cancer tumors. Research efforts are intensifying to elucidate the multitude of cell signaling mechanisms that might be involved in mediating these remarkable anti-cancer and anti-angiogenic effects. The implications are that the next decade will be the dawnof a new era of pharmacotherapeutic applications of medical marijuana treatments in oncology for all cancer types, neurology for all movement disorders, demyelinative and dementia-causing neurodegenerative diseases, rheumatology and gastroenterology for all autoimmune and inflammatory disorders, and palliative care medicine for anxiety and pain management. This publication will include 15 chapters by experts on the use of cannabinoids and medical marijuana in different typesofcancer and different types of neurologic or inflammatory diseases. Some authors will discuss the physiologic and biochemical mechanisms while others will report on clinical benefits and pharmacological challenges"-- $c Provided by publisher.
650 0 $a Marijuana $x Therapeutic use. $3 1155356
650 2 $a Medical Marijuana $x therapeutic use. $3 1427590
650 2 $a Cannabinoids $x analysis. $3 1427591
650 2 $a Neurodegenerative Diseases $x drug therapy. $3 1027367
655 4 $a Electronic books. $2 local $3 554714
700 1 $a Zeine, Rana, $d 1962-. $3 1427588
700 1 $a Teasdale, Brian. $3 1427589
710 2 $a IGI Global. $3 805187
856 4 0 $u http://services.igi-global.com/resolvedoi/resolve.aspx?doi=10.4018/978-1-6684-5652-1